Eurofins receives accreditation to enhance GMP certification credibility
The accreditation demonstrates Eurofins’ adherence to rigorous international quality and competence requirements for certifying products and processes.
LUXEMBOURG – Eurofins Assurance Network has recently achieved ISO/IEC 17065:2012 accreditation from the ANSI National Accreditation Board (ANAB), a significant milestone for its Good Manufacturing Practices (GMP) certification program.
This accreditation is internationally recognised for certifying products, processes, and services, confirming that Eurofins Assurance maintains a robust quality management system and exhibits the technical competence and controls necessary for reliable compliance assessments.
The ISO/IEC 17065 accreditation enhances Eurofins Assurance’s ability to serve industries that demand stringent quality standards, including pharmaceuticals, dietary supplements, and cosmetics.
The certification program encompasses multiple technical scopes, including dietary supplement GMP process certification (compliance with 21 CFR 111/117 & NSF/ANSI 455-2-2024 standards), dietary ingredient GMP, cosmetic GMP (ISO 22716:2007 or NSF/ANSI 455-3-2024), and OTC drug GMP certification (NSF/ANSI 455-4-2024).
This advanced accreditation enhances customer and industry confidence in Eurofins Assurance’s certification services by verifying product safety and quality, thereby supporting brands and retailers that integrate accredited GMP certification into their regulatory compliance programs across their supply chains.
The development aligns with Eurofins Healthcare Assurance’s commitment to meeting regulatory requirements and market demands in the wellness products, dietary supplements, and related sectors globally.
Eurofins H1 FY25 performance highlights
Eurofins reported record revenues of €3.612 billion(USD 4.275 billion ) for the first half of 2025, marking a 5.7% increase year-on-year and the highest revenue level recorded by the company for any six months in its history.
Despite this period traditionally being the weakest half of the year, Eurofins achieved an adjusted EBITDA of €810 million, representing a 7.0% increase from €757 million(USD 779.42 million) in H1 2024.
The adjusted EBITDA margin improved by 30 basis points to 22.4%, aligning with Eurofins’ public goal to enhance profitability beyond the previous year’s results.
The mature business segment, which accounts for 93% of group revenues (€3.361 billion), further improved its adjusted EBITDA margin by 70 basis points to 24.1%, exceeding the company’s 2027 target of 24%.
The non-mature segment, including startups and recent acquisitions, generated €251 million in revenues, up from €189 million(USD 199.66 million) in H1 2024, aided by the acquisition of SYNLAB’s clinical diagnostics operations in Spain during Q2 2025.
Net profit increased by 12.3% year-on-year to €247 million(USD 286.88 million), while basic earnings per share rose 18.4% to €1.20(USD 1.42).
Sign up to receive our email newsletters with the latest news updates and insights from Africa and the World HERE.
